Japan’s Ministry of Health, Labor and Welfare has approved the use of Roche’s (OTCQX:RHHBY -0.6%) Tecentriq (atezolizumab) to treat extensive-phase small cell lung cancer.
The humanized anti-PD-L1 monoclonal antibody was first approved there in January 2018 for previously treated non-small cell lung cancer (NSCLC) and in December 2018 for previously untreated resectable advanced/recurrent NSCLC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.